Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 6/20 | 0.49 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490032 | 0.91 | KDM4E (0.54) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7480943 | 0.89 | HTR1A (0.52) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7484165 | 0.88 | HTR1A (0.55) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7485135 | 0.88 | DRD2 (0.51) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7485709 | 0.87 | NOS3 (0.51) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7482316 | 0.87 | DRD2 (0.50) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7481642 | 0.86 | DRD2 (0.49) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7484250 | 0.86 | NOS3 (0.64) | NOS3NOS1NOS2 | |
| SCHEMBL7489456 | 0.85 | NOS3 (0.49) | HTR1ADRD2HTR2ANOS3NOS1 | |
| SCHEMBL7487433 | 0.85 | NOS3 (0.50) | HTR1ADRD2HTR2ANOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0733628-B9 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0733628-B1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5962474-A | ANALGESICS; HEADACHES | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996029075-A1 | 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0733628-A1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1A 2/4885DRD2 691/4885HTR2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.